Watch: Why there’s so much concern about Trump’s proposed pharma tariffs
Worried about proposed US tariffs on the pharmaceutical industry? Many people are. And ING's Sector Economist, Diederik Stadig, says if they do happen, it'll be mainly the American consumer who'll pay the price.
Read more about Diederik's thinking here
Why there’s so much concern about pharmaceutical tariffs
The global pharmaceutical industry is becoming increasingly concerned about the prospect of drug tariffs. There’s still uncertainty; nothing concrete has been announced yet, but we think they’re coming. President Trump sees the lack of drug production on American soil as a national security threat, and that tariffs will incentivise domestic manufacture. But ING's Diederik Stadig believes they'll just increase prices and shortages, hurting margins, innovation, and, most of all, the American consumer.
This publication has been prepared by ING solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Read more
Download
Download article